{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:54:58Z","timestamp":1785354898725,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s40120-023-00449-w","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T09:02:58Z","timestamp":1677056578000},"page":"597-617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose"],"prefix":"10.1007","volume":"12","author":[{"given":"Borje","family":"Darpo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6949-0963","authenticated-orcid":false,"given":"Michal","family":"Geva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Ferber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yigal Paul","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Cruz-Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munish","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"issue":"5","key":"449_CR1","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/mds.27565","volume":"34","author":"TH Johnston","year":"2019","unstructured":"Johnston TH, Geva M, Steiner L, et al. Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques. Mov Disord. 2019;34(5):708\u201316.","journal-title":"Mov Disord"},{"issue":"11","key":"449_CR2","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3390\/brainsci11111437","volume":"11","author":"A Johri","year":"2021","unstructured":"Johri A, Chandra A. Connection lost, MAM: errors in ER-mitochondria connections in neurodegenerative diseases. Brain Sci. 2021;11(11):1437.","journal-title":"Brain Sci"},{"issue":"2","key":"449_CR3","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1124\/jpet.103.051284","volume":"306","author":"T Hayashi","year":"2003","unstructured":"Hayashi T, Su TP. Sigma-1 receptors (sigma(1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export. J Pharmacol Exp Ther. 2003;306(2):718\u201325.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"449_CR4","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","volume":"131","author":"T Hayashi","year":"2007","unstructured":"Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell. 2007;131(3):596\u2013610.","journal-title":"Cell"},{"key":"449_CR5","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3389\/fnins.2019.00862","volume":"13","author":"DA Ryskamp","year":"2019","unstructured":"Ryskamp DA, Korban S, Zhemkov V, Kraskovskaya N, Bezprozvanny I. Neuronal Sigma-1 receptors: signaling functions and protective roles in neurodegenerative diseases. Front Neurosci. 2019;13:862.","journal-title":"Front Neurosci"},{"issue":"4","key":"449_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/17460441.2021.1838483","volume":"16","author":"T Maurice","year":"2021","unstructured":"Maurice T. Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders. Expert Opin Drug Discov. 2021;16(4):373\u201389.","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"449_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12929-017-0380-6","volume":"24","author":"TY Weng","year":"2017","unstructured":"Weng TY, Tsai SA, Su TP. Roles of sigma-1 receptors on mitochondrial functions relevant to neurodegenerative diseases. J Biomed Sci. 2017;24(1):74.","journal-title":"J Biomed Sci"},{"issue":"2","key":"449_CR8","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s13311-021-01022-9","volume":"18","author":"L Naia","year":"2021","unstructured":"Naia L, Ly P, Mota SI, et al. The sigma-1 receptor mediates pridopidine rescue of mitochondrial function in Huntington disease models. Neurotherapeutics. 2021;18(2):1017\u201338.","journal-title":"Neurotherapeutics"},{"key":"449_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.nbd.2019.05.009","volume":"129","author":"CR Eddings","year":"2019","unstructured":"Eddings CR, Arbez N, Akimov S, et al. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor. Neurobiol Dis. 2019;129:118\u201329.","journal-title":"Neurobiol Dis"},{"issue":"18","key":"449_CR10","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1093\/hmg\/ddw238","volume":"25","author":"M Geva","year":"2016","unstructured":"Geva M, Kusko R, Soares H, et al. Pridopidine activates neuroprotective pathways impaired in Huntington disease. Hum Mol Genet. 2016;25(18):3975\u201387.","journal-title":"Hum Mol Genet"},{"key":"449_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105857","volume":"173","author":"S Lenoir","year":"2022","unstructured":"Lenoir S, Lahaye RA, Vitet H, et al. Pridopidine rescues BDNF\/TrkB trafficking dynamics and synapse homeostasis in a Huntington disease brain-on-a-chip model. Neurobiol Dis. 2022;173: 105857.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"449_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13024-018-0259-3","volume":"13","author":"R Kusko","year":"2018","unstructured":"Kusko R, Dreymann J, Ross J, et al. Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. Mol Neurodegener. 2018;13(1):25.","journal-title":"Mol Neurodegener"},{"issue":"Pt A","key":"449_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.nbd.2016.10.006","volume":"97","author":"D Ryskamp","year":"2017","unstructured":"Ryskamp D, Wu J, Geva M, et al. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiol Dis. 2017;97(Pt A):46\u201359.","journal-title":"Neurobiol Dis"},{"key":"449_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.nbd.2018.12.022","volume":"124","author":"D Ryskamp","year":"2019","unstructured":"Ryskamp D, Wu L, Wu J, et al. Pridopidine stabilizes mushroom spines in mouse models of Alzheimer\u2019s disease by acting on the sigma-1 receptor. Neurobiol Dis. 2019;124:489\u2013504.","journal-title":"Neurobiol Dis"},{"issue":"4","key":"449_CR15","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/jnc.14723","volume":"150","author":"AI Smith-Dijak","year":"2019","unstructured":"Smith-Dijak AI, Sepers MD, Raymond LA. Alterations in synaptic function and plasticity in Huntington disease. J Neurochem. 2019;150(4):346\u201365.","journal-title":"J Neurochem"},{"issue":"2","key":"449_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/jnc.15366","volume":"158","author":"M Shenkman","year":"2021","unstructured":"Shenkman M, Geva M, Gershoni-Emek N, Hayden MR, Lederkremer GZ. Pridopidine reduces mutant huntingtin-induced endoplasmic reticulum stress by modulation of the Sigma-1 receptor. J Neurochem. 2021;158(2):467\u201381.","journal-title":"J Neurochem"},{"key":"449_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15548627.2022.2140882","volume":"4","author":"SM Wang","year":"2022","unstructured":"Wang SM, Wu HE, Yasui Y, et al. Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1\/sigma-1 receptor chaperone by pridopidine. Autophagy. 2022;4:1\u201326.","journal-title":"Autophagy"},{"issue":"11","key":"449_CR18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s004150050272","volume":"245","author":"N Quinn","year":"1998","unstructured":"Quinn N, Schrag A. Huntington\u2019s disease and other choreas. J Neurol. 1998;245(11):709\u201316.","journal-title":"J Neurol"},{"issue":"1","key":"449_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross CA, Tabrizi SJ. Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83\u201398.","journal-title":"Lancet Neurol"},{"issue":"4","key":"449_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2217\/nmt-2016-0008","volume":"6","author":"SS Baig","year":"2016","unstructured":"Baig SS, Strong M, Quarrell OW. The global prevalence of Huntington\u2019s disease: a systematic review and discussion. Neurodegener Dis Manag. 2016;6(4):331\u201343.","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"449_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/mds.25717","volume":"29","author":"ER Fisher","year":"2014","unstructured":"Fisher ER, Hayden MR. Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Mov Disord. 2014;29(1):105\u201314.","journal-title":"Mov Disord"},{"issue":"1","key":"449_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ene.13413","volume":"25","author":"P McColgan","year":"2018","unstructured":"McColgan P, Tabrizi SJ. Huntington\u2019s disease: a clinical review. Eur J Neurol. 2018;25(1):24\u201334.","journal-title":"Eur J Neurol"},{"key":"449_CR23","unstructured":"Brazier Y. What you need to know about Huntington's disease. Medical News Today. 2017. https:\/\/www.medicalnewstoday.com\/articles\/159552. Updated 18 Nov 2021; accessed 11 Dec 2022."},{"key":"449_CR24","unstructured":"Gudesblatt M, Tarsy D. Huntington's disease: a clinical review. Neurol Rev. 2011;S1\u2013S8. https:\/\/www.yumpu.com\/en\/document\/read\/37377029\/huntingtons-disease"},{"issue":"1","key":"449_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.29.1.1","volume":"29","author":"I Shoulson","year":"1979","unstructured":"Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology. 1979;29(1):1\u20133.","journal-title":"Neurology"},{"issue":"2","key":"449_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1212\/WNL.54.2.452","volume":"54","author":"K Marder","year":"2000","unstructured":"Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington\u2019s disease. Huntington Study Group. Neurology. 2000;54(2):452\u20138.","journal-title":"Neurology"},{"issue":"1","key":"449_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","volume":"11","author":"SJ Tabrizi","year":"2012","unstructured":"Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington\u2019s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 2012;11(1):42\u201353.","journal-title":"Lancet Neurol"},{"issue":"7","key":"449_CR28","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","volume":"12","author":"SJ Tabrizi","year":"2013","unstructured":"Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013;12(7):637\u201349.","journal-title":"Lancet Neurol"},{"issue":"12","key":"449_CR29","first-page":"1520","volume":"70","author":"ER Dorsey","year":"2013","unstructured":"Dorsey ER, Beck CA, Darwin K, et al. Natural history of Huntington disease. JAMA Neurol. 2013;70(12):1520\u201330.","journal-title":"JAMA Neurol"},{"issue":"1","key":"449_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jama.2016.8655","volume":"316","author":"S Frank","year":"2016","unstructured":"Huntington Study Group, Frank S, Testa CM, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316(1):40\u201350.","journal-title":"JAMA"},{"key":"449_CR31","doi-asserted-by":"crossref","unstructured":"Shen V, Clarence-Smith K, Hunter C, Jankovic J. Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington's and other diseases. Tremor Other Hyperkinet Mov (N Y). 2013;3:tre-03\u2013191\u20134337\u20131.","DOI":"10.5334\/tohm.129"},{"key":"449_CR32","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3389\/fneur.2019.00710","volume":"10","author":"A-C Bachoud-L\u00e9vi","year":"2019","unstructured":"Bachoud-L\u00e9vi A-C, Ferreira J, Massart R, et al. International guidelines for the treatment of Huntington\u2019s disease. Front Neurol. 2019;10:710.","journal-title":"Front Neurol"},{"issue":"4","key":"449_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3233\/JHD-200440","volume":"9","author":"A McGarry","year":"2020","unstructured":"McGarry A, Leinonen M, Kieburtz K, Geva M, Olanow CW, Hayden M. Effects of pridopidine on functional capacity in early-stage participants from the PRIDE-HD study. J Huntingtons Dis. 2020;9(4):371\u201380.","journal-title":"J Huntingtons Dis"},{"issue":"10","key":"449_CR34","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/mds.25362","volume":"28","author":"Huntington Study Group HART Investigators","year":"2013","unstructured":"Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington\u2019s disease. Mov Disord. 2013;28(10):1407\u201315.","journal-title":"Mov Disord"},{"issue":"12","key":"449_CR35","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","volume":"10","author":"JG de Yebenes","year":"2011","unstructured":"de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington\u2019s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10(12):1049\u201357.","journal-title":"Lancet Neurol"},{"key":"449_CR36","unstructured":"Landwehrmeyer B, Marder K, Biilmann R\u00f8nn, Haglund M. Effects of the dopaminergic stabilizer pridopidine on motor symptoms in Huntington\u2019s disease: a meta-analysis. Poster presented at the World Congress on Huntington\u2019s disease; 2011 Sept 11\u201314; Melbourne, Australia."},{"issue":"6","key":"449_CR37","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1161\/01.CIR.83.6.1888","volume":"83","author":"A Algra","year":"1991","unstructured":"Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation. 1991;83(6):1888\u201394.","journal-title":"Circulation"},{"issue":"10","key":"449_CR38","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013\u201322.","journal-title":"N Engl J Med"},{"key":"449_CR39","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Final concept paper E14 Q&As (R3): revision of ICH E14 Q&As (R2) dated 8 June 2015. Endorsed by the ICH Steering Committee on 9 June 2015. Geneva: ICH Secretariat; 2015."},{"key":"449_CR40","unstructured":"ICH. ICH harmonised tripartite guideline E14. Clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. May 2005. https:\/\/www.ich.org\/page\/efficacy-guidelines. Accessed on 14 Dec 2022."},{"issue":"12","key":"449_CR41","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/jcph.2095","volume":"62","author":"B Darpo","year":"2022","unstructured":"Darpo B, Borin M, Ferber G, et al. ECG evaluation as part of the clinical pharmacology strategy in the development of new drugs: a review of current practices and opportunities based on five case studies. J Clin Pharmacol. 2022;62(12):1480\u2013500.","journal-title":"J Clin Pharmacol"},{"key":"449_CR42","doi-asserted-by":"crossref","unstructured":"Darpo B, Garnett C. Early QT assessment\u2014how can our confidence in the data be improved? Br J Clin Pharmacol. 2013;76(5):642\u20138.","DOI":"10.1111\/bcp.12068"},{"issue":"1","key":"449_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/0091270007307881","volume":"48","author":"C Garnett","year":"2008","unstructured":"Garnett C, Beasley N, Bhattaram VA, et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008;48(1):13\u20138.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"449_CR44","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10928-017-9565-6","volume":"45","author":"C Garnett","year":"2018","unstructured":"Garnett C, Bonate PL, Dang Q, et al. Correction to: scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn. 2018;45(3):399 (Erratum for: J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):383-397).","journal-title":"J Pharmacokinet Pharmacodyn."},{"issue":"3","key":"449_CR45","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","volume":"45","author":"C Garnett","year":"2018","unstructured":"Garnett C, Bonate PL, Dang Q, et al. Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn. 2018;45(3):383\u201397 (Erratum in: J Pharmacokinet Pharmacodyn. 2018 Jan 12).","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"449_CR46","unstructured":"CBER. E14 Clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Guidance for industry. Silver Spring: Center for Biologics Evaluation and Research (CBER), US FDA; 2005."},{"issue":"6","key":"449_CR47","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.ahj.2012.02.023","volume":"163","author":"CE Garnett","year":"2012","unstructured":"Garnett CE, Zhu H, Malik M, et al. Methodologies to characterize the QT\/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects. Am Heart J. 2012;163(6):912\u201330.","journal-title":"Am Heart J"},{"issue":"2","key":"449_CR48","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1474-4422(18)30391-0","volume":"18","author":"R Reilmann","year":"2018","unstructured":"Reilmann R, McGarry A, Grachev ID, et al. Safety and efficacy of pridopidine in patients with Huntington\u2019s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2018;18(2):165\u201376.","journal-title":"Lancet Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00449-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00449-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00449-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T11:32:33Z","timestamp":1679916753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00449-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["449"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00449-w","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"assertion":[{"value":"23 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}